Anamorelin price description in Japanese market

Anamorelin(Anamorelin) is the world's first oral ghrelin receptor agonist approved for the treatment of cancer cachexia. Its unique pharmacological effects make it of great value in supporting nutritional recovery and improving quality of life in cancer patients. The drug promotes appetite and stimulates the secretion of growth hormone and IGF-1 by activating Ghrelin receptors, thereby increasing the proportion of lean body mass in body weight, that is, muscle mass. This mechanism is different from ordinary weight-gaining drugs or nutritional supplements, making it one of the key drugs for cancer patients to "eat and grow back."

In terms of indications, anamorelin is mainly used to treat patients with advanced non-small cell lung cancer, gastric cancer, pancreatic cancer and other patients with cachexia (cachexia). Such patients usually suffer from problems such as loss of appetite, continued weight loss, and muscle loss. Traditional nutritional intervention has limited efficacy. Anamorelin can effectively improve appetite and physical condition, allowing patients to better tolerate chemotherapy or radiotherapy. Japanese clinical guidelines include it as one of the recommended drugs for cancer supportive care, and it is especially widely used in patients with advanced age, long-term weight loss or malnutrition.

Regarding price and market conditions, the original version of Anamorelin marketed in Japan is produced by Ono Pharmaceutical. The common specification is 50 mg × 100 tablets/box. The retail price in the Japanese market is equivalent to about RMB 4,000. The price will fluctuate slightly due to exchange rates and regional differences. Since the drug has not yet been launched in mainland China, domestic patients who need to use it can purchase it through Japanese pharmacies or international medical institutions. At the same time, there are also generic Anamorelin drugs produced by Laos' Luscius Pharmaceutical Factory overseas. Its ingredients are the same as the original drug, but the price is relatively more affordable, about more than 2,000 yuan per box. It is relatively common on some cross-border medical platforms. Judging from international trends, anamorelin is becoming an important part of cancer nutritional therapy.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/